Medicine for weight loss to treat early endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether the medicine tirzepatide, which is used for weight loss, can help women with early-stage endometrial cancer or a pre-cancerous condition avoid or delay surgery. It combines taking tizepatide with a hormonal intrauterine device (Mirena) to try to shrink or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a biopsy showing either early-stage, low-grade endometrial cancer (grade 1 or 2) or a pre-cancerous change (called EIN).
- You must have a BMI above 27 (or above 30 if you have no other health problems) and have decided not to have surgery right away.
- Your cancer must not have spread outside the uterus, based on CT or MRI scans.
- You must be willing to have a small procedure (biopsy) every 3 months and come for monthly check-ups.
- You cannot have had prior treatment for endometrial cancer, pelvic radiation, or certain other cancers in the last 5 years.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This study compares two approaches for women with obesity and early-stage endometrial cancer: having surgery right away versus going through a special weight-loss and health-optimization program before surgery. The goal is to see if preparing the body before surgery improves outcomes.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This trial is testing whether a weight-loss medication called semaglutide combined with a hormonal intrauterine device (IUD) can help treat early-stage endometrial cancer or precancerous changes, allowing patients who want to preserve fertility or avoid surgery to do so. The study also includes a structured weight loss program.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.